Review of Some Applications of Polyoxometalates

Introduction

The purpose of the review is a salute to the heterogenity of polyoxometalates (from now on POMs) chemistry and the innumerable applications in biomedical field as well. Berzelius mentioned about  the POMs  in 1826 and referred to them as “Molybdenum blues”.¹ These are negatively charged oxide anion clusters of early transition metals namely vanadium, niobium in their highest oxidation states. More precisely they are oligomeric aggregates of metal cations with d(0) configuration: V(V), Nb(V), Ta(V).² Today they contribute to development in areas ranging from microelectronics to medical.^3,4 Almost any elements can be incorporated in POMs thus leading to diversity in structures.^5‒8 The species is linked with the help of  oxide anions which form by self-assembly. These are classically heteropoly anions containing oxygen atoms, hydrogen atoms and at least two atoms of other elements. These complexes have relatively stable thermodynamic arrangement. They retain their identities in aqueous, non-aqueous and even in ionic crystals.

Classification of polyoxometalates

There are 2 comprehensive families of polyoxometalates namely

Isopolyoxometalates

Heteropolyoxometalates

In isopolyoxometalate,  metal and oxide are present. It has only one d(0) metal cation. [M_mO_Y]^n- is the general formula.

In heteropolyoxometalate,  metal, oxide and a heteroatom like a silicate, phoshate or any other main group oxyanion are present. It contains one or more p, d or f block elements. The general formula for this may be [M_mO_yX_x]^m-. The heteroatoms in heteropolyoxometalates may be buried or on the surface. As the heteropolyoxometalates are several in count, their structural and electronic properties of these moieties are easier to change compared to isopolyoxometalates.^9,10

Also, the growing family of POMs can be classified as¹¹ transition metal substituted POMs and lanthanide substituted POMs. These types of POMs are formed by modification and incorporation of metal ions. In addition to stabilizing high oxidation state, TMSPOMs offer other advantages as well. By varying the cations present, solubility can be adjusted. Also their redox properties are adjustable. ¹²

When the heteroatom like P or Si tetrahedrally coordinated, the structure is Keggin and Dawson type. Similarly when the heteroatom like Al is octahedrally coordinated, the structure is Anderson type. Lindqvist structure is adopted by hexametalates [M₆O₁₉]^m-. There is an octahedral arrangement of six octahedral. Each octahedra shares it’s four edges and has a compact structure. The lindqvist structure resembles the ccp arrangement of metal oxide. However, the paramolybdate [Mo₇O₂₄]^6- is found to have a bent structure. HeteroPOMs [XM₆O₂₄] ^m- mostly are present in Anderson type of arrangement. The octahedral is formed by sharing of six edges and forming a planar hexagon arrangement around the central metal atom. The tetrahedrally coordinated heteroatom has the common structure resembling as that of Keggin type [XM₁₂O₄₀]ⁿ .There are four trimetallic groups arranged tetrahedrally around central metal atom. [X₂M₁₈O₆₂]^n- has Dawson structure and is found to be a combination of 2 Keggin ions. In the structure, a trimetallic group is removed on each of the Keggin structure and the fragments which remain are joined. Another important type of structure is lacunary structure. This structure is obtained by selectively removing one or more metal ions by adding alkali. Open coordination sites are available which can be occupied by metal or non-metal atoms. The coordination bonds are formed reversibly and the oxo bridges which are formed are cleaved by base. The products thus formed are called lacunary structures. ¹³

Keggin type POM, [XW12O40]^n-, as a member of the heteropolyoxometalates, was first structurally determined by Keggin in the 1930s using X-ray powder diffraction.

Figure 1: Keggin structure of POM13 Click here to View figure

Figure 2: Wells-Dawson structure of POM13 Click here to View figure

It consists central XO₄ tetrahedron surrounded by four triads at each of its vertices.¹⁴ The triads are linked by corner-sharing or edge-sharing with each other. Geometrically, five isomers have been prepared by Baker and Figgis.¹⁵ The α-isomer has tetrahedral geometry and is known to be the most prominent and thermodynamically stable. Rotation of one of the triads by 60⁰ gives rise to β isomer. The γ, δ and ε isomers are also obtained by successive rotation of triads by 60⁰ each.¹⁶

Another well known structure is called Wells-Dawson model. It is formed by two tetrahedral XO₄ . The β, γ-isomers of Wells-Dawson model can be obtained by rotation of one or two W₃O₁₃ groups of α-isomer by 60⁰.¹⁷ Among the six isomers of Dawson structure, 4 have been reported and the α– and β–   isomers are the most common. The trivacant anion, α-[P₂W₁₅O₅₆]12^–, as one of the widely used lacunary POM ligands, is formed by the removal of one W3 “cap” unit from α-{P₂W₁₈}.¹⁸

Functionalized POMs

The  four subcategories of functionalized POMs 

Metal  containing derivatives of POMs

Organometallic derivatives of POMs

Organic derivatives of POMs

Terminal multiple bonded ligands POMs

Metal containing derivative of lacunary POMs

This subclass contains complexes like [PW₁₁O₃₉RhCH₂COOH] which carry a terminal functional group. Various  transition metal derivatives are catalytically used for epoxidation of many  oxidising agents.

Organometallic derivative of POMs

This subcategory of POMs causes immobilization of catalytically active POMs and hence  facilitates the identification of biological destinations of interest.¹⁹

Organic derivatives of POMS

Majorly alkoxo, organosilyl and organophoshoryl derivative are prevalent.^{20, 21}  O- alkylation and esterification of POMs can be used to form alkoxo derivatives. Organosilyl derivatives are obtained by reaction of organochlorosilanes on lacunary POMs. Also self- assembly can give the required POMs.^{22, 23}

Terminal multiple bonded ligands POMs

POMs where the extreme oxo ligands have been replaced by multiple bonded ligands forms the another class of POMs. These can be obtained by performing a reaction analogous to Wittig reaction. Like its other counter parts, this reaction can also take place alternatively by self- assembly.

Overview of POMs

Synthesis

The hydroxo (OH^–) and oxo (O^2-) ligands proceed towards transition metal and encircle them to form complexes in aqueous solution.^24‒26 The higher the charge on metal ion, more easily the protons of ligands dissociate. Thus, cations in their highest oxidation state and fully oxidized form are able to form stable complexes with oxo ligands in aqueous alkaline solutions.

Following this is the acidification of the medium which results in condensation reaction and M-O-M bridges are formed.²⁷ As this process progresses, expansion of coordination number is witnessed which ends up in formation of condensed structures. The characteristics of the POM so formed depends on various conditions like pH, stoichiometry, type of solvent, ambient temperature, concentration and numerous compounds can be formalized by varying any of the above parameters. For example when the pHs is lowered orthometalates (formed at high pH) protonate and give rise to oxide hydroxide compounds. The species thus formed undergoes condensation through a process called “olation”. The condensation is accompanied by the loss of water and M-O-M linkages are formed. When the acidification is performed in presence of phosphates or silicates then we obtain heteropolyoxometalates.

Applications of POMs

The polyoxometalates have innumerable applications in various fields of the world today but the most fascinating one is their applications in medicine. Thus there are several studies going on, in fact, have been occurring since past many decades to study the anti-cancer, anti-viral and anti-bacterial properties of POMs. ^{28, 29, 30, 31,}  

Anticancer studies of POMs

Polyoxomolybdate PM-8

The investigations have been done for the medical applications of polyoxomolybdates as anticancer drugs. Yamase and coworkers recognized the antitumor activities of Anderson type polyoxomolybdate and heptamolybdate had been acknowledged by Yamase and coworkers.^32,33 They explored PM-8 in vivo. [NH₃Prⁱ]₆[Mo₇O₂₄].3H₂O is antitumor POM known as PM-8.³⁴

It was probed to subdue human colon cancer, breast cancer and lung cancer. MKN-45 gastric cancer had been suppressed in mice by this particular POM; the mice had been implanted  with methylcholanthrene induced tumor. PM-8 was administered daily for 9 days after having implanted the tumor cells. Also the inhibition of cell growth of AsPC-1 by PM-8 was observed. Antitumor mechanism of PM-8 resulted from the initiation of programmed cell death pathway. Talking about the properties of PM-8, it is miscible in water, stable complex in aqueous solution in the pH range of 5-7. It can be isolated as ammonium metallic organ metallic salt.³⁵

Polyoxomolybdate: Cancer cell chemotherapeutic and tumor growth  repression

POMs like PM-8, PM-17, PM-26 showcase antitumor activity against  human cancer, MX-1, Co-4 and Meth A mouse sarcoma.³⁶ The chemical formula for PM-8 is hexakis (isopropylammonium) heptamolybdate (VI). From the chemical formula the Mo₇O₂₄ unit is of utmost importance for antitumor activity. ³⁷This Anderson type structure is well known to showcase the anticancerous properties at harmless doses in vivo. On monitoring the effect of POM named PM-8 on human gastric cancer, it was observed that cancer cell growth repression property of the POM was twice as compared to subgroups when tested on tumor bearing mice. It had no harmfull effects such as weight loss in mice.³⁸Talking about the experimental observations, it was revealed that a dose of 100 mg/kg lead to an increase in life span for mice which were implanted with sarcoma tumor cells. On performing a comparative study with approved drugs like 5-fluorouracil it was inferred that PM-8 had more antitumor activity and is less harmful to mice.³⁹

The efficacy of PM-8 against small xenografts (MX-1, OAT human cancer) has been evaluated and it was observed experimentally that PM-8 decelerated the cancerous growth of human breast cancer MX-1 and the tumor size that was identified after 46 days of incubation was only 27%. The antitumor activity of PM-8 against the human colon cancer and the human lung cancer is promising. The patients cannot be cured completely of breast, colon and lung cancer by chemotherapy because of the slow growth rate. In such scenario, PM-8 turns out to be very potent and promising. The anticancer activity is directly linked with polyoxomolybdate anion and the cationic portion controls the solubility and hence the digestibility. ⁴⁰

On carrying out slight modifications to the original PM-8 structure, mixture of reduced species of [H_XMo₇O_24]^6- and one or more Mo^v atoms in aqueous solution, showed anticancer properties against MX-1 xenografts as fully oxidized precursor of PM-8 but the toxicity turned out to be high and led to death of mice during experiment.

Anticancer mechanism of polyoxomolybdate

The mechanism is based on ion redox reaction.

Mechanism:

The POM is altered in such a way:

The [NH₃Pr] cationic part is restored by NH₄⁺ and K⁺. The anion is reinstated by Cl^–. The reduction of [Mo₇O₂₄]^6- to [H_XMo₇O₂₄]^6- leads to execution  of cancer cells. The reaction between [H_XMo₇O₂₄]^6- and host cells leads to the formation of [Mo₇O₂₄]^6- and hence cytotoxicity. [Mo₇O₂₄]^6- thus formed is transmitted to tumor cells and hence they are killed. The structure of this species is thus important for anticancer activity.⁴¹

Experimental analysis

It was revealed by flow cytometry that apoptotic cells ratio raised in the time while administering PM-8 treatment.⁴² Findings showed that tumor cell cytotoxicity mechanisms is apoptosis of tumor cells.

Polyoxotungstate [CoW₁₁TiO₄₀]^8-

Liu, Pope and coworkers examined the cytostatic valuables of heteropolytungstates against tumor cell in vivo.^43‒46 Main focus during the experiment was on the organic derivative of heteropolytungstate containing RSn or CpTi. There turned out to be a direct relation between reduction potential and cytotoxicity. Higher the reduction potential, higher is the cytotoxicity. Encapsulation of [CoW₁₁TiO₄₀]^8- in starch nanoparticles leads to enhanced antitumor activity of polyoxotungstate.⁴⁷

By increasing encapsulation, cell penetration of [CoW₁₁TiO₄₀]^8- is increased hence the efficiency is increased as higher amount of complex is present inside the cells. It was reported that rare earth containing decatungstate led to growth hampering of tumor in mice. 100 mg per kilogram per day was administered that the weight of tumor for 9 days was found to be only 44%. Hence, [CoW₁₁TiO₄₀]^8- in vivo activity was similar to that of cyclophosphamide and 5-FU but its toxicity is lower.⁴⁸

Recent advances in anticancer studies of polyoxometalates

Anticancer activity of polyoxometalate-bisphosphonate complex synthesis

Mo₄ZoI₂Mn (III) is one of the most potent drugs against sarcoma cells in mouse.⁴⁹

Molybdenum (VI) complexes with lipophilic-bisphosphonates were formed by the reaction of  bisphosphonate predecessors with Molybdenum (VI) ions in aqueous solution.⁵⁰ The pH for the reaction was adjusted around 5. The crystals of the mixture could be obtained by slow evaporation for Mo₆ (ZoIC₆)₂. Mo₄ZoI₂Mn (II) was synthesized by reducing Mo₄ZoI₂Mn (III) complex. The reduction could not be performed in aqueous solution, hence to a suspension of crystals present in methanol ascorbic acid was added. On doing so a change in color from grey to yellow was observed. The preparation of Mo₄ (ZoIC₈)₂ Manganese (III) included the reaction between  ZoIC₈  and Mn (OAc)₂ with large amount of Na₂MoO₄ in acetate buffer.

Characterization and structure determination

³¹P NMR was utilized to examine whether the structures identified in solid state were carried on in solution as well. The ³¹P NMR spectrum of Mo₆(ZoIC₆)₂ showed two singlets, one at 17.1 and the other at 16.8 ppm with relative intensities of 0.63:1.37. The same trend was observed for Mo₄(ZoIC₈)₂ with 2 singlets. The presence of another singlet could not be because of free ZoIC₆ ligands as their shift value is around 14. The ³¹P spectra of Mo₆ (ZoIC₆)₂ showed two peaks indicating the stability of complex in aqueous solution.

X-ray diffraction technique was used to illustrate the structure of Mo₆(ZoIC₆)₂. It was found out that there were two independent molecules but each of them had similar inorganic core. In the structure two {Mo₃O₈} units are present. Both of the units are linked through a central oxygen atom and in each trimer Mo (VI) ions are present which are linked to pentadentate bisphosphate ligand by C-O-Mo and P-O-Mo bonds. The Mo (VI) ions lie in a  plane. The difference in both the complexes are observed in the position of C₆ alkyl chain in the imidazole ring. In one of the molecule, it was found that the chain is bent and there are short C-H….O distances (2.33-2.8 A⁰) while in the other molecule, the chain is extended away from the cluster. From IR elemental analysis and EDX measurements it was known that the Mo₄L₂Mn(III) and Mo₄L₂Mn(II) have structures alike  Mo₄L₂Fe, that is, two {Mo₂O₆} dimeric units with face shared Mo(VI) octahedral are bound to octahedral Mn ion and the bisphosphate ligands are connected through P-O-M and C-O-M bonds(M=Mo, Mn).⁵¹

Discussion

The compounds that were synthesized were used to study their effects on tumor cell growth and using the observations, conclusions were made. It was anticipated that the activity of POMs carrying complexes the lipophilic bisphosphate ligands is likely to increase since the bisphosphates acting alone are more active than zoledronate. It was found that the Mo₄L₂Mn (II) complex had more potency approximately 6X more than the activity of zoledronate. For the in-vivo studies, the Mo₄L₂Mn (III) species was used because there were numerous reasons reported namely, it has good activity in lung cancer and breast cancer cell lines. Zoledronate is commercially available while its alkyl derivatives are not there is little difference in activity between Mn (II) and Mn (III) complexes.⁵²

The synthesized POMs were tested against human non small cell lung cancer cell line and the most active compound had IC₅₀ values around 4‒5 µM which turns out to be 6X more potent than Zoledronate. One of the most active compounds was tested against sarcoma cells in mouse xenograft system and the results indicated that there was 5-fold decrease in tumor cell volume as compared to Zoledronate after 28 days treatment period. The results are incredibly interesting as for the first time POM/bisphosphate/Mn complexes have potent in vivo activity. Thus by incorporating bisphosphates into POM it is possible to target Ras as well as EGFR- driven cancers.⁵³

Antiviral studies of POMs

As early as 1970, theinhibitory effect of “silicotungstic acid supernatants” was observed by a group of scientists in Paris.⁵⁴ It was a cell culture which was procured during an experimental procedure in which silicotungstic acid was used. It was subsequently inferred that the prohibitive effect is due to the silicotungstate ion and this led to the study of antiviral activities of polyanions. With the advent to AIDS, the search for antiviral has increased and the use of POMs in this respect has also been encouraged. The anti-HIV property has been reported by almost 50 polyoxometalates.⁵⁵ Polytungtates such as [NMe₃H₇][CH₃C₅H₄TiP₂W₁₇O₆₁] are active as anti-viral agents. POMs show activity against both DNA and RNA viruses like HIV (human immunodeficiency syndrome) and SARS (severe acute respiratory syndrome), influenza RNA virus and herpes DNA simplex virus (HSV).

Cell penetration

The extent of cell penetration alters the mechanism in which the POM performs viral inhibition. POMs are active inside the cytoplasm as well as on the surface of the cell. It is already known that these are negatively charged species and their size in nanometer range. This small size and surface charge hinder the penetration of POMs into the cells. But several evidences have been derived from various techniques and numerous types of experiment which indicate that POMs penetrate into the cell membrane. As an illustration Raman laser spectroscopy was evidently used to provide corroboration for HPA-23 entering C3HBi fibroblast cells. HPA-23: polytungstoantimoniate that was used extensively  during early antiviral research on POMs. HPA acronym used for ‘‘heteropoly acid’’ and the molecular weight for the same is 23.

In vitro antimyxovirus and anti-human immunodeficiency virus activities of POMs

There are POMs which have shown their ability to stop the duplication of retro- paramyxo and herpses viruses. The kind of mechanism adopted by HIV-1 inhibition follows is obstruction by polyoxometalates. They inhibit the binding the viruses to cells. HS-058, the Keggin sandwich type of compound K₁₀Fe₄(H₂O)₂(PW₉O₃₄)₂.H₂O was investigated to have inhibitory action against parainfluenza virus 2 influenza viruses A and B, measles virus and respiratory virus. However, HS-058 did not show any effect on mumps virus or parainfluenza virus 3.⁵⁶

Table1: Chemical formulae andclass of antiviral polyoxometalates⁵⁶

Code No.	Formulae	Class
HS-005	(NH4)17Na[NaSb9W21O86]	Inorganic cryptateKeggin
HS-008	β-H4SiW12O40	Wells-Dawson
HS-010	α-(NH4)6P2W18O62	Preyssier
HS-026	(NH4)14[NaP5W30O110]	Lacunary
HS-042	Na12P2W15O56.18H2O	Wells-Dawson sandwich
HS-052	Na16Ni4(H2O)2(P2W15O56)2.nH2O
HS-053	Na16Mn4(H2O)2(P2W15O56)2.nH2O	Wells-Dawson sandwich
HS-054	Na16Fe4(H2O)2(P2W15O56)2.nH2O	Wells-Dawson sandwich
HS-055	K10Zn4(H2O)2(PW9O34)2.nH2O	Keggin sandwich
HS-056	K10Ni4(H2O)2(PW9O34)2.nH2O	Keggin sandwich
HS-057	K10Mn4(H2O)2(PW9O34)2.nH2O	Keggin sandwich
HS-058	K10Fe4(H2O)2(PW9O34)2.nH2O	Keggin sandwich
HS-083	{(CH3)4N)4SiW11O39O- (SiCH2 CH2CH2CH2CH2CH3)2	Organic derivatized
HS-089	{(CH3)4N)4SiW11O39O-    (SiCH2CH2COOCH3)2	Organic derivatized
HS-091	K8Mn (II)P2W17O61. nH2O	Transition Metal Substituted polyoxometalate
HS-105	(Me3NH)7SiW9Nb3O40.nH2O	Keggin
HS-106	(Me3NH)8Si2W18Nb6O77.nH2O	Dimerized Keggin
HS-131	(Me3NH)5(NbO2)SiW11O39	Keggin peroxo
HS-132	(Me3NH)5NbSiW11O40	Keggin
HS-133	(Me3NH)5 (TaO2)SiW11O39	Keggin peroxo
HS-136	(Me3NH)7(NbO2)2SiW9O37	Keggin peroxo
HS-146	K7NbP2W17O62	Wells-Dawson
HS-157	K12(NbO2)6P2W12O56	Wells-Dawson peroxo
HS-158	K12Nb6P2W12O62	Wells-Dawson

Discussion

It was inferred that POMs have a broad spectrum of antiviral activity. Since the agents responsible for the cause of viral respiratory infections are not identifiable at clinical level hence it becomes imperative to use broad spectrum antiviral drug to prevent the progress of the infection. Hence HS-058 which is a powerful antiviral drug against the FluV-A, FluV-B, and other viruses is a very promising antiviral. During the examination various POMs were investigated and among them HS-054 turned out to have higher antiviral activity and lesser toxicity than its counterparts. The observation was also made that several polyoxometalates that had anti-HIV 1 activity were also influential against FluV-A virus.⁵⁷

Antibacterial studies of POMs

β-lactam antibiotics such as penicillin can stop the construction of cell wall in bacteria hence hindering the growth of bacterial culture and thus acting as antibacterial agents. But the resistance which the bacteria are developing against these drugs is posing a huge health issue. Over time some bacteria have evolved to produce β-lactamases which hydrolyses the β-lactam ring which is present in antibiotics hence rendering them ineffective. Even bacteria have developed resistance against penicillin by changing their penicillin-binding-proteins (PBP) and such penicillin resistant bacteria are a huge threat.

Tajima⁵⁸ described about the effectiveness of an aged mixture of phosphate and tungstate. It  was in amalgamation with β-lactam antibiotics. He invented a “T” factor and according to him this factor highly increased the antibacterial effect of drug in MRSA strains. He studied about the mechanism of factor T and inferred that it lowered the amount of PBP-2 and stimulated strains to β-lactams. Factor T was afterwards  recognized as lacunary Keggin polyoxotungstate and the discovery was further extended on about 70 POMs in combination with β-lactam antibiotics.⁵⁹ Polyoxomolybdate, vanadate, metavanadate are adsorbed less by cells than polyoxotungstates. The collaborative power of polyoxotungstates is lowered in presence of polycations say, for example, polylysine as they have a tendency to form ion pairs with negatively charged complexes. Decatungstates which have Anderson type structures are found to have lesser synergistic effect than Keggin  species. The lacunary Keggin type species has more potency than the parent saturated [PW₁₂O₄₀]^3-. The polyoxotungtate [CoSiW₁₁O₃₉]^6- is an appropriate example of balance between toxicity and sensitizing effect. The existence of mini cations increases the stimulating effect of the polyoxotungstate. Keggin ion [PTi₂W₁₀O₄₀]^7- stops the formation of PBP-2 and lowers the production of β-lactamases which also contributes to the cooperative effects with β-lactam antibiotics. Yamase mentioned about the antibacterial effect of polyoxovanadate against 6 strains of penicillin resistant pneumonia.⁶⁰

Recent advances in the antibacterial studies of polyoxometalates: [Tl₂{B-β-SiW₈O₃₀ (OH)}₂]

The first distinct thallium containing POM has been synthesized and characterized which showed anti-bacterial properties as well. The POM is [Tl₂{B-β-SiW₈O₃₀(OH)}₂] and this has been characterized in solid state and it is stable in solution as well. Various techniques like 203 Tl and 205 Tl NMR, mass spectrometry, electrospray ionization, and electrochemical studies made the characterization possible. It has been reported that Tl containing metal oxides having extended structure.⁶¹ The structure of hexagonal tungsten bronze A_XWO_3, first described by Magneli in 1953.⁶² In 1980, Towene’s group described a Tl subdue Keggin ion based on elemental analysis.⁶³ Tl³⁺ undergoes hydrolysis in aqueous solution and formed thallium hydroxo complexes begins at pH 0.5.⁶⁴ 203 Tl and 205 Tl NMR spectroscopy depicting spin-spin coupling between thallium atoms is a powerful tool to study structure. In the structure, two Tl³⁺ ions present are octahedrally coordinated and are sandwiched between the 2 lacunary Keggin type structures.⁶⁵

Characterization

In solid state, IR spectroscopy was and done by KBr pellet method. Using X-ray diffraction, it was found out that POM crystallizes in monoclinic system with C_2h symmetry. 2 Tl³⁺ ions were present and 2 {B-β-SiW₈O₃₀(OH)}₂] units.⁶⁶ In 2005, the first POM was discovered that contained [ B-β-SiW₈O₃₁].⁶⁷ There are 2 Tl³⁺ ions present which are octahedrally coordinated and each Tl ion is coordinated to 2 [ B-β-SiW₈O₃₁] fragments through 4 terminal O atoms of 2 complete tungsten oxo triads and 2 terminal O atoms of two {SiO₄} hetero groups. Tl-O bond length was found to be 2.156-2.238 A⁰ and distance between two Tl atoms was found to be 3.338 A⁰. BVS (bond valence sum) calculations revealed that the oxidation state of Tl is +3. Elemental analysis revealed that the POM is diprotonated and BVS calculations suggested 2 µ₃-O atoms.⁶⁸ From 203 Tl AND 205 Tl NMR spectroscopy, spectra appeared pseudotriplets due to spin-spin coupling between two sterically similar Tl atoms and the central peaks were obtained due to 205 Tl- 205 Tl or 203 Tl- 203 Tl atoms coupling. In the similar way, satellite peals were obtained by 205 Tl- 203 Tl heteronuclear coupling. ¹H couplings had no role to play because of fast exchange.

Antibacterial activity

Minimum inhibitory concentration (MIC) of the antibacterial POM was found to be comparable to the Tl(NO₃)₂ and Tl(OOCCH₃)₃ and the latter is known as inorganic antibacterial against Gram-negative bacteria. Both Tl salts were found to have similar activity in phosphate buffer. Tl³⁺ salt are insoluble while POM is. POM showed high antibacterial activity against Gram-positive bacteria, exhibiting 32-fold increased activity comparatively to plain Tl³⁺ or Tl²⁺ ions.

Conclusion

The study revealed that the polyoxometalates has evolved present days because the study of anionic POMs and it reactivity still continues to fascinate the researchers till date owing to the magnificent properties and vast area of application of polyoxometalates. The polyoxometalates have immense potential to act as drugs which are economical and more powerful as well as effective than prevalent organic drugs in market today. An exchange between chemistry and biology will assist in development of bio-medical applications of POMs. Which  gives rise to afresh and promising feasibilities in molecular biology and in the detection and treatment of diseases. In near future, it is likely that, with the advances in research in applications of Polyoxometalates in medicine, they will be available for curing diseases and giving intensive competition to comparatively expensive organic drugs.

Acknowledgements

I acknowledge all the co-authors and Maharshi Dayanand university for their constant support.

Conflict of interest

There is no conflict of interest.

References

1. Berzelius, J. J.  Poggendorfs. Ann. Phys. Chem. 1826, 6, 369.
   CrossRef
2. Pope, M. T. Heteropoly and Isopoly Oxometalates, Springer-Verlag: Berlin 1983.
   CrossRef
3. Hill, C. L.  Chem. Rev. 1998, 98, 1-2.
   CrossRef
4. Katsoulis, D. E. Chem. Rev. 1998, 98,  359-388.
   CrossRef
5. Pope, M. T. In comprehensive coordination Chemistry, Springer Verlag, Berlin, 1983.
6. Pope, M. T.; Muller A. Kluwer Academic Publishers, Dordrecht, 1994.
7. Pope, M. T.;  Muller A. Kluwer Academic Publishers, Dordrecht, 2001.
8. Borras Almenar, J. J.; Coronado, E.; Muller, A.;  Pope, M. T. Kluwer Academic Publishers,   Dordrecht, 2003.
9. Tajima, Y.  Curr. Top. in Biochem. Res.  2001,4, 129-136.
10. Rhule, J. T.;  Hill, C. L.; Judd,  D. A.; Schinazi, R. F.; Chem.  Rev. 1998, 98, 327-357.
    CrossRef
11. Car P. E. and  Patzke  G. R. Inorganics. 2015, 3, 511-515.
    CrossRef
12. Ismail, A. H. Thesis: synthesis and structural characterization of lanthanide-containing polyoxometalates, Jacobs University, 2011.
13.  Hasenknopf B.  Front. in biosci. 2005, 275-287.
    CrossRef
14. Brown, G. M.; Noe-Spirlet, M. R.; Busing, W. R.; Levy, H. A. Acta Cryst. B. 1977, B33, 1038.
    CrossRef
15. Baker, L. C. W.;  Figgis, J. S. J. Am. Chem. Soc. 1970, 92, 3794-3797.
    CrossRef
16. Hill, C. L.;  Brown, R. B. Jr. J. Am. Chem. Soc. 1986, 108, 536.
    CrossRef
17. Dawson, B.  Acta Cryst. B. 1953, 6, 113-126.
    CrossRef
18. Baker, L. C. W.;  Figgis, J. S.  J. Am. Chem. Soc. 1970, 92, 3794-3797.
    CrossRef
19. Proust, A.;  Villanneau, R.; Delmont, R.; Artero, V.; Gouzerh, P. Eds: Pope, M. T.; Müller, A. Kluwer Academic Publishers, Dordrecht, 2001,55-67.
20. Gouzerh, P.;  Proust, A. Chem. Rev. 1998, 98, 77-112.
    CrossRef
21. Hasenknopf, B.; Delmont, R.; Herson, P. Eur. J. of Inorg. Chem. 2002, 1081-1087.
    CrossRef
22. Mayer, C. R.;  Herson, P.;  Thouvenot R.  Inorg. Chem. 1999,38, 6152-6158.
    CrossRef
23. Mazeaud, A.; Dromzee, Y.; Thouvenot, R.  Inorg. Chem. 2000,39, 4735-4740.
    CrossRef
24. Souchay, P.  Polyanions et Polycations. Gauthiers-Villars, Paris, 1963.
25. Souchay, P. Ions Mineraux Condenses. Masson, Paris, 1969.
26. Jolivet, J. P. Metal oxide chemistry and synthesis: From solution to solid state, John Wiley & Sons, New York, 2001.
27. Pope, M. T. Molybdenum oxygen chemistry: Oxides oxo complexes and polyoxoanions. In. Progress in inorganic chemisty. Ed: S. J. Lippard, John Wiley & Sons, New York, 1991, 181-255.
    CrossRef
28. Oghli, A. H.; Soleymanpour, A. Mat. Sci. and Eng.  C. 2020, 108, 110407.
    CrossRef
29. Ventura, D.;  Calderan, A.; Honisch, C.; Krol, S.; Serratì, S.; Bonchio, M.;  Ruzza, P. Pept. Sci. 2018, 110(5).
30. Yang, H. K.; Cheng, Y. X.; Su, M. M.; Xiao, Y.; Hu, M. B.; Wang, W.; Wang, Q. Bioorgan. & med. Chem.. lett. 2013, 23(5), 1462-1466.
    CrossRef
31. Ni, D.; Jiang, D.; Valdovinos, H. F.; Ehlerding, E. B.; Yu, B.; Barnhart, T. E.; Haung, P.;  Cai, W. Nano lett. 2017, 17(5), 3282-3289.
    CrossRef
32. Yamase, T.  Mol. Eng. 1993,3, 241-262.
    CrossRef
33. Yamase, T.; Fujita, H.; Fukushima, K.; Seto, Y. In: PCT Int. Appl 68, Terumo Corp., Japan, Wo, 1988.
34. Yamase, T.; Fujita, H.; Fukushima, K.  Inorg. Chim. Acta. 1998, 151, 15-18.
    CrossRef
35.  Guedes, G.; Wang, S.; Santos, H. A.; Sousa, F. L. Eur. J. of Inor. Chem. 2020 (22), 2121-2132.
    CrossRef
36. Yanagie, H.; Ogata, A.; Mitsui, S.; Hisa, T.; Yamase, T.; Eriguchi, M. Biomed. and Pharmaco. 2006, 60, 349-352.
    CrossRef
37.  Mitsui, S.;  Ogata, A.; Yanagie, H.; Kasano, H.;  T. Hisa, T.;  Yamase, T.; Eriguchi, M. Biomed. & Pharmaco. 2006, (60), 353–358.
    CrossRef
38.  Fujita, H.; Fujita, T.; Sakurai, T.; Seto, Y. Chemotherapy. 1992, (40), 173–8.
39.  Yamase, T. Inorg Chim Acta. 1988, 151,15–8.
    CrossRef
40.   Yamase T. Inorg Chim Acta. 1990, 169, 147–50.
    CrossRef
41. Fukuda, N.; Yamase, T.; Tajima, Y.  Biol Pharm Bull. 1999, 22, 463–70.
    CrossRef
42. Wang, X. H.; Dai, H. C.; Liu, J. F. Polyhedron 1999, 18, 2293.
    CrossRef
43. She, S.;  Bian, S.;  Hao, J.;  Zhang, J.; Zhang, J.;  Wei, Y. Chem. –  A Eur. J. 2014, 20, 16987-16994.
    CrossRef
44. Zheng, S. T.; Yang, G. Y.  Chem. Soc. Rev. 2012, 41, 7623-7646.
    CrossRef
45. Wang, S. S.; Yang, G.Y. Chem. Rev. 2015, 115, 4893-4962.
    CrossRef
46. Liu, J. F.;  Chen, Y. G.;  Meng, L.; Guo, J.; Liu Y.; Pope, M.T.  Am. Chem. Soc. 1998, 17, 1541- 1546.
    CrossRef
47. Wang, X.; Liu,  J.; Pope, M. T. Am. Chem. Soc. 2003, 5, 957-960.
    CrossRef
48.  Wang X, Liu J, Li J, Yang Y, Liu J, Li B, Pope MT.  J Inorg Biochem 2003;94:279–84.
    CrossRef
49.   El Moll, H.; Zhu, W.; Oldfield, E.; Rodriguez-Albelo, L. M.; Mialane, P.; Marrot, J.; Vila, N.; Mbomekallé, I. M.; Riviere, E.; Duboc, C.; Dolbecq, A. Inorg. Chem. 2012, 51, 7921.
    CrossRef
50.   Thiel, J.; Ritchie, C.; Streb, C.; Long, D. L.; Cronin, L. J. Am. Chem. Soc. 2009, 131, 4180
    CrossRef
51.  Zhang, Y.; Cao, R.; Yin, F.; Hudock, M. P.; Guo, R. T.; Krysiak, K.; Mukherjee, S.; Gao, Y. G.; Robinson, H.; Song, Y.; No, J. H.; Bergan, K.; Leon, A.; Cass, L.; Goddard, A.; Chang, T. K.; Lin, F. Y.; Beek, E. V.; Papapoulos, S.; Wang, A. H.; Kubo, T.; Ochi, M.; Mukkamala, D.; Oldfield, E.  J. Am. Chem. Soc. 2009, 131, 5153.
    CrossRef
52.  Saad, A.; Zhu, W.; Rousseau, G.; Mialane, P.; Marrot, J.; Haouas, M.; Taulelle, F.; Dessapt, R.; Serier-Brault, H.; Rivière, E.; Kubo, T.; Oldfield, E.; Dolbecq, A.  Chem. Eur. J. 2015, 21, 10537.
    CrossRef
53.  Xia, Y.; Liu, Y.-L.; Xie, Y.; Zhu, W.; Guerra, F.; Shen, S.; Yeddula, N.; Fischer, W.; Low, W.; Zhou, X.; Zhang, Y.; Oldfield, E.; Verma, I. M. Sci. Transl. Med. 2014, 6, 263ra161.
    CrossRef
54. Boulmier, A.;  Xinxin, F.; Mialane, P.  Am.  Chem. Soc. 2017, 56, 7558-7565.
    CrossRef
55. Chermann, J. C.; Raynaud, M.; Jasmin, C.; Mathe, G. Nature. 1970,227, 173-174.
    CrossRef
56. Shigeta, S.; Mori, S.; Watanabe, J. Antiviral Chemistry & Chemotherapy. 1995, 6,114- 122.
    CrossRef
57. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A.  Science 1996, 272, 872-877.
    CrossRef
58. Mukherjee, S.;  Huang, C.;  Guerra, K.;  Wang, K.;  Oldfield, E. J. Am. Chem. Soc. 2009, 131,  8374-8375.
    CrossRef
59. Dong, Z.;  Corbett, J. D.  J. Am. Chem. Soc. 1994, 116, 3429−3435.
    CrossRef
60. Kamata, K.; Yonehara, K.; Sumida, Y.; Yamaguchi, K.; Hikichi, S. Mizuno, N. Science 2003, 300, 964-966.
    CrossRef
61. Dong, Z. C.;  Henning, R. W.;  Corbett, J. D.  Inorg. Chem. 1997, 36, 3559−3561.
    CrossRef
62. Oms, O.;  Dolbecq, A.; Mialane,  P.  Chem. Soc. Rev. 2012, 41, 7497−7536.
    CrossRef
63. Zonnevijlle, F.; Tourné, C. M.  Inorg. Chem. 1982, 21, 2742−2750.
    CrossRef
64. Winter, R. S.;  Long, D. L.;  Cronin, L.  Inorg. Chem. 2015, 54, 4151−4155.
    CrossRef
65. Kohguchi, K.; Ede, K. I.;  Sagara, Y.;  Nakamura, M. Kurume Med. J. 1969, 16, 163−168.
    CrossRef
66. Ayass, W.; Fodor, T.; Lin, Z.  Am. Chem. Soc. 2016, 55,10118-10121.
    CrossRef
67. Winter, R. S.;  Long, D. L.;  Cronin, L.  Inorg. Chem. 2015, 54, 4151−4155.
    CrossRef
68. Brown,  I. D.; Altermatt, D. Struct. Sci. 1985, 41, 244−247.
    CrossRef

Abbreviations

Sr. No.	Abbreviation	Explanation
1.	POMs	Polyoxometalates
2.	Meth A	Murine tumor
3.	MXI	Breast all line
4.	Mo v	Molybdenum (v)
5.	V (v)	Vanadium (v)
6.	Ta (v)	Tanatanum (v)
7.	PM-8	[NH3Pri]6 [Mo7O24]
8.	RSn	Alkyntin
9.	CpTi	cyclopantyltitanium
10.	HIV	Human immunodeficiency virus
11.	DNA	Deoxy ribonucleic acid
12.	RNA	Ribonucleic acid
13.	SARS	Severe acute respiratory syndrome
14.	HPA-23	Polytangsto antimoniate
15.	PBP	Penicillin binding protein
16.	MRSA	Methicillin resistant staphy
17.	BUS	Bond valence sum
18.	TMSPOMs	Transition metal substituted polyoxometalatas
19.	MKN-45	Gastric cancer cell line
20.	EGFR	Epidermal growth factor receptor

 

---

This work is licensed under a Creative Commons Attribution 4.0 International License.